Search research articles
Contact Us
Filters
Showing results (11-20 of 76) with videos related to
Page
of 8
Sort By:
Journal of Personalized Medicine
|
July 27, 2024
Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?
Laura Calabrese, Martina D'Onghia, Laura Lazzeri, et al.
Italian Journal of Dermatology and Venereology
|
January 22, 2025
Belimumab as a potential therapeutic option for bullous systemic lupus erythematosus
Carolina Donelli, Cristiana Barreca, Laura Calabrese, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 10, 2025
Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials
Laura Calabrese, Alessandra Cartocci, Pietro Rubegni, et al.
Pharmaceutics
|
December 23, 2022
Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis
Lorenzo Maria Pinto, Andrea Chiricozzi, Laura Calabrese, et al.
The British Journal of Dermatology
|
January 6, 2022
Therapeutic potential of targeting interleukin-1 family cytokines in chronic inflammatory skin diseases
Laura Calabrese, Zeno Fiocco, Takashi K Satoh, et al.
Journal of Clinical Medicine
|
June 19, 2024
Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition
Martina Dragotto, Martina D'Onghia, Emanuele Trovato, et al.
Clinical and Experimental Rheumatology
|
May 31, 2024
Clinical response to brodalumab in a patient affected by refractory SAPHO syndrome
Emilio D'Ignazio, Emanuele Trovato, Luca Cantarini, et al.
Dermatology Practical & Conceptual
|
May 22, 2025
Upadacitinib for Treatment-Resistant Urticarial Vasculitis: A Case Study and Therapeutic Insight
Francesca Falcinelli, Edoardo Conticini, Luca Cantarini, et al.
Expert Opinion on Investigational Drugs
|
February 28, 2023
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new?
Laura Calabrese, Dalma Malvaso, Flaminia Antonelli, et al.
Journal of Clinical Medicine
|
September 14, 2024
Uncovering the Differences: How DLQI and WHO-5 Scores Vary in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab 100 mg vs. 200 mg?
Emanuele Trovato, Martina Dragotto, Eugenio Capalbo, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 76) with videos related to
Sort By:
Page
of 8
Journal of Personalized Medicine
|
July 27, 2024
Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?
Laura Calabrese, Martina D'Onghia, Laura Lazzeri, et al.
Italian Journal of Dermatology and Venereology
|
January 22, 2025
Belimumab as a potential therapeutic option for bullous systemic lupus erythematosus
Carolina Donelli, Cristiana Barreca, Laura Calabrese, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 10, 2025
Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials
Laura Calabrese, Alessandra Cartocci, Pietro Rubegni, et al.
Pharmaceutics
|
December 23, 2022
Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis
Lorenzo Maria Pinto, Andrea Chiricozzi, Laura Calabrese, et al.
The British Journal of Dermatology
|
January 6, 2022
Therapeutic potential of targeting interleukin-1 family cytokines in chronic inflammatory skin diseases
Laura Calabrese, Zeno Fiocco, Takashi K Satoh, et al.
Journal of Clinical Medicine
|
June 19, 2024
Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition
Martina Dragotto, Martina D'Onghia, Emanuele Trovato, et al.
Clinical and Experimental Rheumatology
|
May 31, 2024
Clinical response to brodalumab in a patient affected by refractory SAPHO syndrome
Emilio D'Ignazio, Emanuele Trovato, Luca Cantarini, et al.
Dermatology Practical & Conceptual
|
May 22, 2025
Upadacitinib for Treatment-Resistant Urticarial Vasculitis: A Case Study and Therapeutic Insight
Francesca Falcinelli, Edoardo Conticini, Luca Cantarini, et al.
Expert Opinion on Investigational Drugs
|
February 28, 2023
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new?
Laura Calabrese, Dalma Malvaso, Flaminia Antonelli, et al.
Journal of Clinical Medicine
|
September 14, 2024
Uncovering the Differences: How DLQI and WHO-5 Scores Vary in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab 100 mg vs. 200 mg?
Emanuele Trovato, Martina Dragotto, Eugenio Capalbo, et al.
Page
of 8